Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients

NCT05338723 is registered in ClinicalTrials.gov with Tanta University as lead sponsor.

NCT NCT05338723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05338723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients
Lead sponsor
Tanta University
Phase
Phase 3
Overall status
Completed
Start date
September 15, 2020
Completion date
September 15, 2023
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, chemotherapy-induced cardiotoxicity